Takeda Pharmaceutical (TAK) Liabilities and Shareholders Equity (2018 - 2026)

Takeda Pharmaceutical's Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $98.3 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 1.53% year-over-year to $98.3 billion; the TTM figure through Jun 2026 stood at $395.5 billion (up 2.13% YoY), while the FY2026 annual figure was $103.0 billion, up 10.16% from the prior year.
• Liabilities and Shareholders Equity for Q2 2026 stood at $98.3 billion, down from $98.9 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $113.4 billion in Q1 2022, with the low at $93.4 billion in Q1 2025.
• The 5-year median for Liabilities and Shareholders Equity is $99.7 billion (2024), against an average of $101.4 billion.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity dropped 14.43% in 2022, then climbed 5.91% in 2026.
• Takeda Pharmaceutical's Liabilities and Shareholders Equity stood at $95.6 billion in 2022, then rose by 0.66% to $96.2 billion in 2023, then climbed by 3.27% to $99.4 billion in 2024, then climbed by 0.76% to $100.1 billion in 2025, then dropped by 1.85% to $98.3 billion in 2026.
• Business Quant data shows TAK's Liabilities and Shareholders Equity at $98.3 billion in Q2 2026, $98.9 billion in Q1 2026, and $100.1 billion in Q4 2025.